Files
statdx/docs_md/articles/amyotrophic-lateral-sclerosis-als_23de52b7-d9bd-441c-a18c-95c8afccb470.md
Ross 9c86b32c3b .
2025-10-20 21:15:33 +01:00

34 KiB
Raw Permalink Blame History

title, docid, authors, breadcrumbs, category, documentVersionId, imageCount, lastUpdated, pageDescription, pageKeywords, pageTitle, enhancedTitle, type, references, tables, breadcrumbs
title docid authors breadcrumbs category documentVersionId imageCount lastUpdated pageDescription pageKeywords pageTitle enhancedTitle type references tables breadcrumbs
Amyotrophic Lateral Sclerosis (ALS) 23de52b7-d9bd-441c-a18c-95c8afccb470
key value
1fa14dfd-71ea-4960-908e-e720313bc63a Santhosh Gaddikeri, MD
key value
a25c450b-3d34-4f64-bba3-cc0834813df6 Miral D. Jhaveri, MD, MBA
name slug treeNodeId
Brain brain 6d8829f1-14d7-45af-8675-255189aa526a
name slug treeNodeId
Diagnosis diagnosis 51c00394-446e-4a38-94af-d3b1d14d34e8
name slug treeNodeId
Pathology-Based Diagnoses pathology-based-diagnoses d9d3a8ed-f21b-4831-8c77-591a3500ef77
name slug treeNodeId
Acquired Toxic/Metabolic/Degenerative Disorders acquired-toxicmetabolicdegenerativ- ba3cfeaf-64d9-4117-91e8-d2ce58783fc5
name slug treeNodeId
Dementias and Degenerative Disorders dementias-and-degenerative-disorde- 6381104d-7a4c-4be5-bb19-3cd90837d547
name slug treeNodeId
Amyotrophic Lateral Sclerosis (ALS) amyotrophic-lateral-sclerosis-als null
Brain 136628b7-37b6-40ed-b5bc-ab6b976a211d 23 09/30/20 Amyotrophic Lateral Sclerosis (ALS) Brain, Diagnosis, Pathology-Based Diagnoses, Acquired Toxic/Metabolic/Degenerative Disorders, Dementias and Degenerative Disorders, Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis (ALS) | STATdx Amyotrophic Lateral Sclerosis (ALS) DX true 1
Brain
Diagnosis
Pathology-Based Diagnoses
Acquired Toxic/Metabolic/Degenerative Disorders
Dementias and Degenerative Disorders
Amyotrophic Lateral Sclerosis (ALS)

title: "Amyotrophic Lateral Sclerosis (ALS)" docid: "23de52b7-d9bd-441c-a18c-95c8afccb470" authors:

  • key: "1fa14dfd-71ea-4960-908e-e720313bc63a" value: "Santhosh Gaddikeri, MD"
  • key: "a25c450b-3d34-4f64-bba3-cc0834813df6" value: "Miral D. Jhaveri, MD, MBA" breadcrumbs:
  • name: "Brain" slug: "brain" treeNodeId: "6d8829f1-14d7-45af-8675-255189aa526a"
  • name: "Diagnosis" slug: "diagnosis" treeNodeId: "51c00394-446e-4a38-94af-d3b1d14d34e8"
  • name: "Pathology-Based Diagnoses" slug: "pathology-based-diagnoses" treeNodeId: "d9d3a8ed-f21b-4831-8c77-591a3500ef77"
  • name: "Acquired Toxic/Metabolic/Degenerative Disorders" slug: "acquired-toxicmetabolicdegenerativ-" treeNodeId: "ba3cfeaf-64d9-4117-91e8-d2ce58783fc5"
  • name: "Dementias and Degenerative Disorders" slug: "dementias-and-degenerative-disorde-" treeNodeId: "6381104d-7a4c-4be5-bb19-3cd90837d547"
  • name: "Amyotrophic Lateral Sclerosis (ALS)" slug: "amyotrophic-lateral-sclerosis-als" treeNodeId: null category: "Brain" documentVersionId: "136628b7-37b6-40ed-b5bc-ab6b976a211d" imageCount: 23 lastUpdated: "09/30/20" pageDescription: "Amyotrophic Lateral Sclerosis (ALS)" pageKeywords: "Brain, Diagnosis, Pathology-Based Diagnoses, Acquired Toxic/Metabolic/Degenerative Disorders, Dementias and Degenerative Disorders, Amyotrophic Lateral Sclerosis (ALS)" pageTitle: "Amyotrophic Lateral Sclerosis (ALS) | STATdx" enhancedTitle: "Amyotrophic Lateral Sclerosis (ALS)" type: "DX" references: true tables: 1 breadcrumbs:
  • "Brain"
  • "Diagnosis"
  • "Pathology-Based Diagnoses"
  • "Acquired Toxic/Metabolic/Degenerative Disorders"
  • "Dementias and Degenerative Disorders"
  • "Amyotrophic Lateral Sclerosis (ALS)"

KEY FACTS

  • Terminology

    • Amyotrophic lateral sclerosis (ALS)
    • Selective degeneration of somatic motor neurons of brainstem/spinal cord & large pyramidal neurons of motor cortex - Eventual loss of corticospinal tract (CST) fibers
  • Imaging

    • Small percentage demonstrate CST hyperintensity
    • As CST is normally slightly hyperintense, especially at 3.0 T, this finding lacks sensitivity & specificity
    • T2-hyperintense CST may be specific for ALS when seen on corresponding PD images
    • Consider FLAIR & PD in suspected ALS
    • DWI hyperintensity (↓ diffusivity) in CST
    • Hypointense gray matter in precentral gyrus (motor cortex)
  • Top Differential Diagnoses

    • Primary lateral sclerosis
    • Wallerian degeneration
    • Hypertrophic olivary degeneration
    • Metabolic diseases involving bilateral CSTs
    • Demyelinating & inflammatory diseases
    • Neoplasms: Brainstem glioma, malignant lymphoma
    • CST can appear hyperintense on 3T MR normally
  • Pathology

    • Majority of ALS cases are sALS
    • 5-10% are familial (fALS)
  • Clinical Issues

    • UMN signs: Babinski sign, spasticity, hyperreflexia
    • LMN signs: Asymmetric muscle weakness, atrophy, fasciculations, hyporeflexia
    • Bulbar signs: Slurred speech, dysphagia
    • Classic ALS: Both UMN & LMN affected
    • Peaks in 6th-8th decades of life
    • Complete disability & death within 1 decade
    • Some patients with familial, juvenile-onset ALS survive for longer periods (2-3 decades)

TERMINOLOGY

  • Abbreviations

    • Amyotrophic lateral sclerosis (ALS)
  • Synonyms

    • Lou Gehrig disease, motor neuron disease (MND)
  • Definitions

    • Selective degeneration of somatic motor neurons of brainstem/spinal cord {lower motor neurons (LMN) & large pyramidal neurons of motor cortex [upper motor neurons (UMN)]} - Eventual loss of corticospinal tract (CST) fibers

IMAGING

  • General Features

    • Best diagnostic clue

      - Bilateral hyperintensities along CST extending from corona radiata to brainstem on T2WI/PD/FLAIR
      
    • Location

      - Hallmark is CST & LMN degeneration
              - LMN in anterior horn of spinal cord & brainstem
              - Corticospinal UMN in precentral gyrus (motor cortex)
      - White matter (WM) & gray matter (GM)
      - Frequently, prefrontal motor neurons involved in planning or orchestrating work of UMN & LMN
      
    • Size

      - Atrophy of motor system, particularly pyramidal tract, in advanced stages of ALS
      
    • Morphology

      - Oval or thin, curvilinear hyperintensities conforming to CST
      
  • CT Findings

    • NECT

      - Serial CT exams may show progressive atrophy
              - Frontal, anterior temporal lobes → precentral gyrus → postcentral gyrus, anterior cingulate gyrus, corpus callosum, tegmentum
      
  • MR Findings

    • T1WI

      - Different T1 appearances of CST
              - Isointensity (most common) may reflect ↑ content of free radicals
              - Hypointense or mild hyperintense signal
              - CST differs between ALS patients & normal subjects only at internal capsule
      - T1 hyperintensity in anterolateral cervical cord is associated with younger patients & rapid disease progression
      
    • T2WI

      - Hyperintense CST
      - Hyperintensity can occur anywhere from subcortical WM of precentral gyrus to posterior limb internal capsules, cerebral peduncles, & pons
      - As CST is normally slightly hyperintense especially at 3.0 T, this finding lacks sensitivity & specificity
      - T2 hyperintense CST may be specific for ALS when seen on corresponding PD images
      - Hypointense GM in precentral gyrus (motor cortex)
              - Nonspecific; may be due to iron & heavy metals accumulating in cortex of aged patients
      
    • PD/intermediate

      - Hyperintense CST
      
    • FLAIR

      - More sensitive & less specific than T2 FSE for detecting hypointensity in precentral gyrus
      - Hyperintense CST
              - More frequently seen on FLAIR than on T2/T1/PD
      
    • T2* GRE

      - Hypointensity in precentral gyri
      
    • DWI

      - Hyperintensity in CST
              - May be seen in absence of T2 hyperintensity
      
    • Diffusion tensor imaging (DTI) - ROI-based approaches & tractography demonstrates significant changes in diffusion parameters along CST - Most common finding: ↓ fractional anisotropy (FA) in CST due to UMN degeneration - ↓ FA in CST; most significant in posterior limb internal capsule & correlates with disease severity - ↑ mean diffusivity (MD) along CST which correlates with disease duration - ↑ MD in corpus callosum, frontal & temporal WM - ↓ FA & ↑ MD in cervical cord correlate with disease severity & duration respectively

    • ¹H-MRS useful for assessing UMN involvement - ↓ NAA, ↓ NAA/Cr, ↓ NAA/Cho, & ↓ NAA/(Cr + Cho) in motor cortex - NAA present primarily in neurons; these metabolic changes reflect loss or dysfunction of motor neurons - ↓ NAA/Cr:NAA/Cho ratio along CST; most pronounced in precentral gyrus & corona radiata - ↓ NAA in pons & upper medulla in patients with prominent UMN or bulbar signs - ↑ Cho in posterior limb internal capsule - ↑ myo-inositol (mI) in motor cortex - ↓ NAA:mI ratio has better sensitivity & specificity in detecting ALS than any other metabolites

    • Magnetization-transfer ratio (MTR) measurements - ↓ MTR in CST - CST hyperintensity on T1 MT contrast-enhanced images: 80% sensitivity, 100% specificity - May detect CST degeneration of ALS at early stage

    • Voxel-based morphometry (VBM) - Regional GM loss in motor cortex, frontal, temporal, parietal, & limbic regions - Frontal severe atrophy in ALS & frontotemporal dementia - WM loss in corpus callosum, cerebellum, frontotemporal, & occipital regions - ↓ Brain parenchymal fraction (BPF) & very mild global brain atrophy

    • Functional MR - Pattern of cortical reorganization - ↑ activation of contralateral sensorimotor cortex, supplementary motor area, basal ganglia, & cerebellum during motor tasks

  • Nuclear Medicine Findings

    • PET, Tc-99m HMPAO SPECT - ↓ regional cerebral metabolism/perfusion throughout brain with marked changes in sensorimotor cortex & putamen - ↑ ALS severity correlated with ↓ GM perfusion
  • Imaging Recommendations

    • Best imaging tool: MR with T2, PD, FLAIR, DTI

DIFFERENTIAL DIAGNOSIS

PATHOLOGY

  • General Features

    • Etiology

      - Sporadic ALS (sALS) etiology is largely unknown
      - Proposed potential mechanisms include
              - Abnormal RNA processing, SOD1-mediated toxicity, excitotoxicity, cytoskeletal derangements, mitochondrial dysfunction
              - Viral infections, apoptosis, growth factor abnormalities, & inflammatory responses
      - Pathological hallmarks include loss of MNs with intraneuronal ubiquitin-immunoreactive inclusions in UMN & TDP-43 immunoreactive inclusions in degenerating LMN
      - ↑ expression of cyclooxygenase-2 in spinal cord, frontal cortex, & hippocampus
      - Apoptosis, free radical-mediated oxidative stress, excessive glutamate-mediated excitotoxicity
      - Dopamine deficiency probably has important role
      - Biochemical studies have shown ↓ glutamate levels in CNS tissue & ↑ levels in CSF
      - Mutations in single gene can lead to selective degeneration of motor neurons
      
    • Genetics

      - 90-95% of cases are sALS
      - 5-10% of cases are familial (fALS)
              - Most common ALS-related gene mutation occurs in *C9ORF72*, *SOD1*, *TARDBP*, & *FUS*
                        - In European population: Most common is *C9ORF72*repeats
                        - In Asian population: Most common is *SOD1* mutation
      - Rare autosomal recessive juvenile-onset ALS
              - *ALS2* gene on chromosome 2q encodes alsin
      
    • Associated abnormalities

      - ALS-plus syndrome: MND with other symptoms or signs outside of voluntary motor system
              - 23% of cases, ALS is accompanied by frontotemporal dementia
              - ~ 50% of cases show cognitive impairment
      - Can be associated with frontotemporal dementia (FTD), autonomic insufficiency, parkinsonism, supranuclear gaze paresis, &/or sensory loss
      - ALS-like MND can occur as paraneoplastic syndrome
      
  • Gross Pathologic & Surgical Features

    • Focal atrophy of motor cortex & along course of CST
    • Atrophy of anterior & lateral portions of spinal cord
  • Microscopic Features

    • Loss of cortical motor neurons (pyramidal & Betz cells) & astrocytosis
    • Retrograde axonal loss & gliosis in CST
    • "Senescent changes" with lipofuscin pigment atrophy
    • Various cytoplasmic inclusions with chromatolysis
    • Proximal & distal axonopathy with axonal spheroids
    • Surviving motor neurons are smaller & abnormal
    • Frequently undetected CST pathology in progressive muscular atrophy variant of ALS
    • Bunina bodies (eosinophilic aggregates are positive for cystatin C) are unique for ALS
    • Other intracellular inclusions: Neurofilament inclusions, ubiquitinated inclusions, TDP-43 inclusions, & immunoreactive inclusions toFUS

CLINICAL ISSUES

  • Presentation

    • Most common signs/symptoms

      - UMN signs: Babinski sign, spasticity, hyperreflexia
      - LMN signs: Asymmetric muscle weakness, atrophy, fasciculations, hyporeflexia
              - Split-hand syndrome: Frequent pattern of weakness & atrophy in ALS involving thenar muscles more than hypothenar muscles
      - Bulbar signs: Slurred speech, dysphagia
      - Difficulty walking, unexplained weight loss
      - Hypoxia, cardiac arrhythmia
      
    • Other signs/symptoms

      - El Escorial criteria diagnosis of ALS: Evidence of UMN findings, LMN findings, & progression
              - 4 regions or levels: Bulbar, cervical, thoracic, lumbosacral
      
    • Clinical profile

      - Classic ALS: Both UMN & LMN affected
      - UMN-dominant ALS can be difficult to distinguish from primary lateral sclerosis
      - Predominantly bulbar form usually leads to more rapid deterioration & death
      - fALS associated with *SOD1* abnormality has mean age at 42 years limb onset, slow evolution
      
  • Demographics

    • Age

      - Peaks in 6th to 8th decades; can occur in young adults
      
    • Sex

      - M:F = 1.5:1.0
      
    • Ethnicity

      - Slightly higher in Non-Hispanics white population
      
    • Epidemiology

      - Incidence: 1-3 cases/100,000 people
      - Prevalence: 2.7-7.4 cases/100,000 people
      
  • Natural History & Prognosis

    • Progressive (distal to proximal) - Median survival from diagnosis to death: 3-4 years - 10% of patients survive > 10 years
    • Some patients with familial, juvenile-onset ALS survive for longer periods (2-3 decades)
  • Treatment

    • Riluzole (glutamate release inhibitor & insulin-like growth factor) may prolong survival - ↑ NAA/Cr in precentral gyrus & supplementary motor area after riluzole therapy - This suggests population of sublethally injured, metabolically compromised neurons that are amenable to therapeutic rescue
    • No improvement in perirolandic neuronal integrity (no change in NAA:Cr ratio) was detected after gabapentin treatment, which agrees with equivocal clinical effectiveness
    • Baclofen, dantrolene, or diazepam for spasticity

DIAGNOSTIC CHECKLIST

  • Consider

    • FLAIR & PD MR in all patients with suspected ALS
  • Image Interpretation Pearls

    • High T2 signal intensity in posterior limb of IC is suggestive for ALS when also visible on PD MR
    • T1- & PD-weighted images differentiate real degeneration from normal areas
    • DTI can assess CST lesions before pyramidal symptoms

c693ffa3-6052-4eb1-8840-2ce1ab8bebf8

References

Selected References

  1. Braun N et al: The revised El Escorial criteria "clinically probable laboratory supported ALS"-once a promising now a superfluous category? Amyotroph Lateral Scler Frontotemporal Degener. 1-5, 2019
  2. Lai JD et al: C9ORF72 protein function and immune dysregulation in amyotrophic lateral sclerosis. Neurosci Lett. 134523, 2019
  3. Barthel H et al: PET/MR in dementia and other neurodegenerative diseases. Semin Nucl Med. 45(3):224-33, 2015
  4. Goveas J et al: Diffusion-MRI in neurodegenerative disorders. Magn Reson Imaging. 33(7):853-76, 2015
  5. Verstraete E et al: Neuroimaging as a new diagnostic modality in amyotrophic lateral sclerosis. Neurotherapeutics. 12(2):403-16, 2015
  6. Chiò A et al: Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. 13(12):1228-40, 2014
  7. Vucic S et al: Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 37(8):433-42, 2014
  8. Wang S et al: Neuroimaging in amyotrophic lateral sclerosis. Neurotherapeutics. 8(1):63-71, 2011
  9. Filippi M et al: EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. Eur J Neurol. 17(4):526-e20, 2010
  10. Wijesekera LC et al: Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 4:3, 2009
  11. Sage CA et al: Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage. 34(2):486-99, 2007
  12. Unrath A et al: Brain metabolites in definite amyotrophic lateral sclerosis. A longitudinal proton magnetic resonance spectroscopy study. J Neurol. 254(8):1099-106, 2007
  13. Kalra S et al: Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol. 253(8):1060-3, 2006
  14. Cosottini M et al: Diffusion-tensor MR imaging of corticospinal tract in amyotrophic lateral sclerosis and progressive muscular atrophy. Radiology. 237(1):258-64, 2005
  15. Sach M et al: Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain. 127(Pt 2):340-50, 2004
  16. Kalra S et al: Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol. 24(3):476-80, 2003
  17. Kalra S et al: Neuroimaging in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 4(4):243-8, 2003
  18. Strong M et al: Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord. 4(3):136-43, 2003
  19. Heath PR et al: Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 26(4):438-58, 2002
  20. Bowen BC et al: MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol. 21(4):647-58, 2000
  21. Chan S et al: Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology. 212(3):763-9, 1999
  22. Ellis CM et al: Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 53(5):1051-8, 1999
  23. Kato Y et al: Detection of pyramidal tract lesions in amyotrophic lateral sclerosis with magnetization-transfer measurements. AJNR Am J Neuroradiol. 18(8):1541-7, 1997
  24. Mascalchi M et al: Corticospinal tract degeneration in motor neuron disease. AJNR Am J Neuroradiol. 16(4 Suppl):878-80, 1995

Tables

European Federation of Neurological Societies Guidelines on Use of Neuroimaging in Management of Motor Neuron Disease

Role of MR in Diagnosis of Amyotrophic Lateral Sclerosis
Conventional MR is restricted to exclude other causes of signs and symptoms of motor neuron pathology
Corticospinal tract T2 hyperintensities and precentral gyrus T2-hypointense rim can support preexisting suspicion of motor neuron disease; specific search of these abnormalities for purpose of making firm diagnosis of motor neuron disease is not recommended
Currently advanced neuroimaging techniques (including DTI and MRS) have no role in diagnosis/routine monitoring of motor neuron diseases
Advanced neuroimaging techniques are strongly recommended to be incorporated into new clinical trials

Images

Selected Images

A 56-year-old man with a clinical diagnosis of amyotrophic lateral sclerosis (ALS) presents with progressive bilateral lower extremity weakness (he has been wheelchair bound for 6 months of symptom onset). Axial DWI MR shows hyperintense signal in posterior limb of bilateral internal capsules . A 56-year-old man with a clinical diagnosis of amyotrophic lateral sclerosis (ALS) presents with progressive bilateral lower extremity weakness (he has been wheelchair bound for 6 months of symptom onset). Axial DWI MR shows hyperintense signal in posterior limb of bilateral internal capsules .

Coronal T2 MR in the same patient shows hyperintense signal along the bilateral corticospinal tract (CST) , more prominent in the internal capsule and cerebral peduncles. Coronal T2 MR in the same patient shows hyperintense signal along the bilateral corticospinal tract (CST) , more prominent in the internal capsule and cerebral peduncles.

Axial FLAIR MR in the same patient shows hyperintense signal in the posterior limbs of bilateral internal capsule along the CSTs . Axial FLAIR MR in the same patient shows hyperintense signal in the posterior limbs of bilateral internal capsule along the CSTs .

Axial 3D SWI in the same patient at the level of vertex shows rim of low signal in bilateral precentral gyri (motor cortex) . This finding is nonspecific and may be due to iron and heavy metals accumulating in the cortex of older patients. Axial 3D SWI in the same patient at the level of vertex shows rim of low signal in bilateral precentral gyri (motor cortex) . This finding is nonspecific and may be due to iron and heavy metals accumulating in the cortex of older patients.

A 52-year-old male patient with ALS presenting with progressive bilateral lower extremity weakness followed by upper extremity weakness is shown. Axial T2WI (top)  and FLAIR (bottom)   show hyperintense signal involving the internal capsules posterior limb. A 52-year-old male patient with ALS presenting with progressive bilateral lower extremity weakness followed by upper extremity weakness is shown. Axial T2WI (top) and FLAIR (bottom) show hyperintense signal involving the internal capsules posterior limb.

Axial SWI in same patient shows linear low signal along bilateral motor cortex . EMG shows degeneration and chronic reinnervation in a multisegmental distribution, consistent with motor neuron disease. Axial SWI in same patient shows linear low signal along bilateral motor cortex . EMG shows degeneration and chronic reinnervation in a multisegmental distribution, consistent with motor neuron disease.

Axial DWI MR shows oval hyperintensities corresponding to CSTs in the pons . DWI/DTI can help differentiate progressive muscular atrophy [no change in fractional anisotropy (FA) or mean diffusivity (MD)] from ALS (↑ MD, ↓ FA), which can be clinically difficult. Axial DWI MR shows oval hyperintensities corresponding to CSTs in the pons . DWI/DTI can help differentiate progressive muscular atrophy [no change in fractional anisotropy (FA) or mean diffusivity (MD)] from ALS (↑ MD, ↓ FA), which can be clinically difficult.

Sagittal T1WI MR shows atrophy of the posterior corpus callosum body . DTI showed ↓ FA in the corpus callosum. Voxel-based morphometry has high sensitivity in detecting local tissue atrophy in the motor cortex and along the CSTs. Sagittal T1WI MR shows atrophy of the posterior corpus callosum body . DTI showed ↓ FA in the corpus callosum. Voxel-based morphometry has high sensitivity in detecting local tissue atrophy in the motor cortex and along the CSTs.

Axial T2WI FS MR shows central cortical hypointense signal intensity    in the precentral gyri due to iron deposition. While this is common in ALS patients, it is nonspecific and may be seen in older patients due to iron and heavy metals accumulation. Axial T2WI FS MR shows central cortical hypointense signal intensity in the precentral gyri due to iron deposition. While this is common in ALS patients, it is nonspecific and may be seen in older patients due to iron and heavy metals accumulation.

Axial T2* SWI MR demonstrates curvilinear hypointensity along the cortical gray matter of bilateral precentral gyri . The T2* SWI technique accentuates the T2 hypointensity seen in the precentral gyrus gray matter of ALS patients. Axial T2 SWI MR demonstrates curvilinear hypointensity along the cortical gray matter of bilateral precentral gyri . The T2* SWI technique accentuates the T2 hypointensity seen in the precentral gyrus gray matter of ALS patients.*

Additional Images

Axial ADC map in the same ALS patient appears normal. Axial ADC map in the same ALS patient appears normal.

Axial DWI MR shows increased signal involving subcortical white matter of both precentral (motor) gyri, extending caudally into CSTs (not shown). These findings are typical for ALS. Axial DWI MR shows increased signal involving subcortical white matter of both precentral (motor) gyri, extending caudally into CSTs (not shown). These findings are typical for ALS.

Axial T2WI MR in the same patient shows hyperintense CSTs  at the level of the cerebral peduncle. (Courtesy O.Q. Castro, MD.) Axial T2WI MR in the same patient shows hyperintense CSTs at the level of the cerebral peduncle. (Courtesy O.Q. Castro, MD.)

Coronal T2WI MR shows hyperintense CSTs  in a patient with ALS. (Courtesy O.Q. Castro, MD.) Coronal T2WI MR shows hyperintense CSTs in a patient with ALS. (Courtesy O.Q. Castro, MD.)

Axial T2WI MR in the same patient shows symmetrical high signal intensity in corona radiata fibers corresponding to CSTs. Axial T2WI MR in the same patient shows symmetrical high signal intensity in corona radiata fibers corresponding to CSTs.

Axial T2WI MR in the same patient demonstrates bilateral low signal intensity in the precentral (motor) cortex . Axial T2WI MR in the same patient demonstrates bilateral low signal intensity in the precentral (motor) cortex .

Axial T2WI MR in the same patient with ALS shows symmetric hyperintense CSTs  at the level of the cerebral peduncle. Axial T2WI MR in the same patient with ALS shows symmetric hyperintense CSTs at the level of the cerebral peduncle.

Axial T2WI MR in a young man with ALS shows symmetric hyperintense CSTs  at the level of the internal capsule. Axial T2WI MR in a young man with ALS shows symmetric hyperintense CSTs at the level of the internal capsule.

Axial DWI MR shows small foci of hyperintensity in the posterior limbs of bilateral internal capsules  in this ALS patient. Axial DWI MR shows small foci of hyperintensity in the posterior limbs of bilateral internal capsules in this ALS patient.

Axial T2 MR in a patient with ALS shows hyperintensity along the course of the CST   bilaterally. Important to note that CST is typically slightly hyperintense on T2 especially at 3.0 T. Axial T2 MR in a patient with ALS shows hyperintensity along the course of the CST bilaterally. Important to note that CST is typically slightly hyperintense on T2 especially at 3.0 T.

Axial DTI trace image shows symmetric hyperintensity in the internal capsule posterior limbs . FA correlates with measures of disease severity and UMN involvement, whereas the MD correlates with disease duration. Axial DTI trace image shows symmetric hyperintensity in the internal capsule posterior limbs . FA correlates with measures of disease severity and UMN involvement, whereas the MD correlates with disease duration.

Axial T2WI FS MR demonstrates ovoid hyperintensity along the CSTs bilaterally . Atrophy and hyperintense foci is due to myelin loss and gliosis. There is frequently involvement of prefrontal motor neurons that play a role in planning or orchestrating the work of the upper and lower motor neurons. Axial T2WI FS MR demonstrates ovoid hyperintensity along the CSTs bilaterally . Atrophy and hyperintense foci is due to myelin loss and gliosis. There is frequently involvement of prefrontal motor neurons that play a role in planning or orchestrating the work of the upper and lower motor neurons.

Coronal FLAIR MR shows linear hyperintensity  along the CST from the precentral gyrus to the cerebri crus. Right CST signal abnormality is out of this imaging slice. Hyperintensity of the precentral gyrus subcortical white matter on FLAIR is a potentially useful and specific sign of ALS that is not seen in healthy, asymptomatic patients. Coronal FLAIR MR shows linear hyperintensity along the CST from the precentral gyrus to the cerebri crus. Right CST signal abnormality is out of this imaging slice. Hyperintensity of the precentral gyrus subcortical white matter on FLAIR is a potentially useful and specific sign of ALS that is not seen in healthy, asymptomatic patients.